Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Calithera Biosciences, Inc.CALA · Entity 113073 | Director | June 01, 2022 | June 03, 2022 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Exec VP & CFO | December 12, 2016 | December 15, 2016 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | Director | June 30, 2020 | July 01, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Calithera Biosciences, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2032-05-31 | Direct | 20,000 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 20,000 · Balance 20,000 F1: 1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction.
SANGAMO THERAPEUTICS, INC
Report date December 12, 2016 · Filed December 15, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,829 |
Reported balance
After 2015-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2015-12-12 · Tax withholding · Disposed 13,778 · Balance 206,829 F1: Represents shares withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting and issuance of RSUs. F2: Includes 12,500 and 25,000 shares subject to RSUs granted on December 11, 2014 and December 8, 2015 respectively, which will be issued as such units vest in accordance with their terms. F3: Includes an aggregate of 4,904 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on October 31, 2015, April 30, 2016 and October 31, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting and issuance of RSUs.
F2: Includes 12,500 and 25,000 shares subject to RSUs granted on December 11, 2014 and December 8, 2015 respectively, which will be issued as such units vest in accordance with their terms.
F3: Includes an aggregate of 4,904 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on October 31, 2015, April 30, 2016 and October 31, 2016.
Viracta Therapeutics, Inc.
Report date June 30, 2020 · Filed July 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2030-06-30 | Direct | 60,000 |
Reported balance
After 2020-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-30 · Grant · Acquired 60,000 · Balance 60,000 F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 17,960 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 59,092 · Balance 0 F3: In connection with the Merger, these options were accelerated and canceled without payment. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2021-12-15 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 5,520 · Balance 0 F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2022-09-01 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: In connection with the Merger, these options were accelerated and canceled without payment.
F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Jun 3, 2022 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000899243-22-020930 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-31 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 1, 2022, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0000899243-21-023542 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 11, 2021, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,377 | $0.06 Strike: $17.94 | $682.62 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · derivative · entry 6 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F4 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F4 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Options (Right to Buy) · Derivative | 5,000 | $11.00 Strike: $7.00 | $55,000.00 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · derivative · entry 5 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-09-01 F4 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F4 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Options (Right to Buy) · Derivative | 5,520 | $11.00 Strike: $7.00 | $60,720.00 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · derivative · entry 4 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,520 shares Expires 2021-12-15 F4 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F4 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 59,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · derivative · entry 3 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,092 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F3 · price: In connection with the Merger, these options were accelerated and canceled without payment. F3 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F3 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerRestricted Stock Units | 7,281 | $18.00 | $131,058.00 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · nonDerivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:41 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 17,960 | $18.00 | $323,280.00 |
DisclosureSEC source: 0001209191-20-040380 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:55 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000899243-20-018136 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:23 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 11,377 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-20-036794 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 19:23 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 7,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036794 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,241 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 16:03 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000899243-20-016153 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 9, 2020, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 17:21 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000899243-19-018921 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:42 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,991 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001209191-19-037470 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:42 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 4,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037470 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,960 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 2,000 | $27.55 | $55,103.80 |
DisclosureSEC source: 0001209191-19-034804 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Henry & Marian Wolff 1999 Revocable Trust Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Subsequent to Reporting Person's acquisition of 5,000 shares through a cash exercise on March 12, 2019, Reporting Person transferred 2,000 shares into the Henry & Marian Wolff 1999 Revocable Trust for which Reporting Person is a trustee. F2 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2019. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.13 to $27.98, inclusive. The Reporting Person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:07 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.42 | $0.00 |
DisclosureSEC source: 0000899243-19-015385 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 30, 2019, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:17 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-19-019575 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:17 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,000 | $5.10 | $25,500.00 |
DisclosureSEC source: 0001209191-19-019575 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 19:33 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001179110-18-009415 · edgar.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2028-06-29 F2 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:27 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-18-036772 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:27 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036772 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,766 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000899243-18-014882 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-05-30 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from May 31, 2018, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| February 28, 2018 Filed Jul 3, 2018 19:33 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001179110-18-009415 · edgar.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2028-02-28 F1 · derivative.exercise_date: The option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two (2) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 20:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 700 | $47.77 | $33,438.02 |
DisclosureSEC source: 0001209191-17-066238 · doc4.xml · nonDerivative · entry 3 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Henry & Marian Wolff 1999 Revoc. Trust Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.55 to $47.93, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 20:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 11,300 | $46.95 | $530,512.40 |
DisclosureSEC source: 0001209191-17-066238 · doc4.xml · nonDerivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Henry & Marian Wolff 1999 Revoc. Trust Disclosed balance after: 700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.44 to $47.38, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:30 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Options (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001209191-17-056355 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2017-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 20:30 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 12,000 | $5.30 | $63,600.00 |
DisclosureSEC source: 0001209191-17-056355 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Dec 18, 2017 20:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001209191-17-066238 · doc4.xml · derivative · entry 4 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2017-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: Mr. Wolff exercised these shares through a cash exercise and transferred the shares following the exercise into the Henry & Marian Wolff 1999 Revocable Trust for which Mr. Wolff is a trustee. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017. Read SEC document |
| October 05, 2017 Filed Dec 18, 2017 20:02 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 12,000 | $5.30 | $63,600.00 |
DisclosureSEC source: 0001209191-17-066238 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Henry & Marian Wolff 1999 Revoc. Trust Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 18:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $35.06 | $0.00 |
DisclosureSEC source: 0001209191-17-040930 · doc4.xml · derivative · entry 2 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest each month after June 1, 2017, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 18:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040930 · doc4.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 16:35 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000899243-17-016234 · doc4.xml · derivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: 1/12 of the Option vests in each monthly installment as measured from June 09, 2017, until the earlier of the Option's full vesting or the reporting person ceasing to provide continuous service to the issuer. In addition, in the event of a Change in Control or a Corporate Transaction (each as defined in the plan pursuant to which the Option was granted), any unvested portion of the Option will fully vest and become exercisable as of immediately prior to the effective time of such Change in Control or Corporate Transaction, subject to the reporting person's continuous service on the effective date of such transaction. Read SEC document |
| December 12, 2015 Filed Dec 15, 2016 01:03 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 13,778 | $3.05 | $42,022.90 |
DisclosureSEC source: 0001140361-16-089715 · doc1.xml · nonDerivative · entry 1 Wolff Henry Ward · CIK 0001302390 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,829 F1 · shares: Represents shares withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting and issuance of RSUs. F2 · balance_after: Includes 12,500 and 25,000 shares subject to RSUs granted on December 11, 2014 and December 8, 2015 respectively, which will be issued as such units vest in accordance with their terms. F3 · balance_after: Includes an aggregate of 4,904 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on October 31, 2015, April 30, 2016 and October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.